Amit Arora, MD | |
39400 Paseo Padre Pkwy, Fremont, CA 94538-2310 | |
(510) 248-3000 | |
Not Available |
Full Name | Amit Arora |
---|---|
Gender | Male |
Speciality | Hematology/oncology |
Experience | 31 Years |
Location | 39400 Paseo Padre Pkwy, Fremont, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386722130 | NPI | - | NPPES |
00A776570 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | A77657 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kaiser Foundation Hospital - Fremont | Fremont, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Researchers have successfully created artificial human muscles in the laboratories that are tiny but fully functional. These small muscles actually respond to the nerve stimulations, says the latest study reporting this scientific breakthrough.
Researchers say that using the lower limit of normal of the forced expiration volume in 1 second/forced vital capacity ratio improves risk stratification in patients with chronic obstructive pulmonary disease undergoing thoracic surgery.
Even if hospital workers practice perfect hand hygiene, MRSA can still spread among babies in the NICU, according to new research led by a Drexel University researcher.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
› Verified 9 days ago
Entity Name | Permanente Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Researchers have successfully created artificial human muscles in the laboratories that are tiny but fully functional. These small muscles actually respond to the nerve stimulations, says the latest study reporting this scientific breakthrough.
Researchers say that using the lower limit of normal of the forced expiration volume in 1 second/forced vital capacity ratio improves risk stratification in patients with chronic obstructive pulmonary disease undergoing thoracic surgery.
Even if hospital workers practice perfect hand hygiene, MRSA can still spread among babies in the NICU, according to new research led by a Drexel University researcher.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Amit Arora, MD 39400 Paseo Padre Pkwy, Fremont, CA 94538-2310 Ph: (510) 248-3000 | Amit Arora, MD 39400 Paseo Padre Pkwy, Fremont, CA 94538-2310 Ph: (510) 248-3000 |
News Archive
Researchers have successfully created artificial human muscles in the laboratories that are tiny but fully functional. These small muscles actually respond to the nerve stimulations, says the latest study reporting this scientific breakthrough.
Researchers say that using the lower limit of normal of the forced expiration volume in 1 second/forced vital capacity ratio improves risk stratification in patients with chronic obstructive pulmonary disease undergoing thoracic surgery.
Even if hospital workers practice perfect hand hygiene, MRSA can still spread among babies in the NICU, according to new research led by a Drexel University researcher.
Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.
› Verified 9 days ago
Dr. Lakshmi Srinivasan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3200 Kearney St, Fremont, CA 94538 Phone: 510-490-1222 | |
Srilata Raman, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-248-3623 | |
Hannelore Mohr, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Frederick G. Hom, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Dr. Michael Andre Lenoir, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3448 Mowry Ave, Fremont, CA 94538 Phone: 510-373-3000 Fax: 844-965-9795 | |
Julie Yue Zhou, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Soham P Jhaveri, Do, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3200 Kearney St, Fremont, CA 94538 Phone: 510-490-1222 |